Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein

Q is a member selected from the group consisting of —C(O)—, —CH 2 CO—, —CH 2 SO— and —CH 2 SO 2 —;

L is a bond or (C 1 -C 5 )alkylene;

A 1 , A 2 and A 3 are independently selected from the group consisting of C(R′)(R″) and C(O);

A 4 is C(R′)(R″) or N(R′″);

each R′ and R″ is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )heteroalkyl, fluoro(C 1 -C 4 )alkyl, aryl, heteroaryl, aryl(C 1 -C 8 )alkyl and heteroaryl(C 1 -C 8 )alkyl, optionally, R′ and R″ groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and R′ and R″ groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring;

R′″ is selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl and (C 2 -C 8 )heteroalkyl;

R 1 is heteroaryl or aryl;

R 2 is selected from the group consisting of hydrogen, halogen, (C 1 -C 10 )alkyl, (C 2 -C 10 )heteroalkyl, hetero(C 1 -C 10 )cycloalkyl, (C 1 -C 10 )alkylaryl and (C 2 -C 10 )heteroalkylaryl, optionally R 2 may be combined with L to form a 5-, 6-, 7- or 8-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S;

R 3 is absent or is a member selected from the group consisting of —H, —CHR 6 R 7 , S(O) m R 5 , —S(O) m N(R 8 )R 9 , —S(O) m N(R 8 )CH 2 R 6 , —N(R 8 )SO 2 R 5 , —N(R 8 )CH 2 R 10 ,

 wherein

R 5 is selected from the group consisting of (C 1 -C 8 )alkyl, (C 2 -C 8 )heteroalkyl, aryl and heteroaryl;

R 6 and R 7 independently are hydrogen, (C 1 -C 8 )alkyl or (C 2 -C 8 )heteroalkyl,

R 8 is hydrogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )heteroalkyl, heteroaryl or aryl,

R 9 is (C 1 -C 8 )alkyl;

R 10 is aryl,

Z is CH or N,

X is a bond, (C 1 -C 6 )alkylene or (C 1 -C 6 )heteroalkylene,

Y is (C 1 -C 6 )alkylene;

the subscript m is 0, 1 or 2; or

optionally, R 3 may be combined with R 2 to form a 4-, 5-, 6-, 7- or 8-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S; and

R 4 is a member selected from the group consisting of (C 1 -C 20 )alkyl, (C 2 -C 20 )heteroalkyl, heteroaryl, aryl, heteroaryl(C 1 -C 6 )alkyl, heteroaryl(C 2 -C 6 )heteroalkyl, aryl(C 1 -C 6 )alkyl and aryl(C 2 -C 6 )heteroalkyl.

2. The compound of claim 1 , wherein R 1 is para-cyanophenyl.

3. The compound of claim 1 , having the formula (Ia):

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein A 4 is N(R′″).

5. The compound of claim 3 , wherein A 1 , A 2 and A 3 are C(R′)(R″).

6. The compound of claim 3 , having the formula (II):

or a pharmaceutically acceptable salt thereof, wherein

each R a is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )heteroalkyl, fluoro(C 1 -C 4 )alkyl, aryl, heteroaryl, aryl(C 1 -C 8 )alkyl and heteroaryl(C 1 -C 8 )alkyl, or optionally, R a groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and R a groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring; and

the subscript k is 0, 1, 2, 3 or 4.

7. The compound of claim 6 , wherein R′″ is —CH 3 , —CH 2 CH 3 or —C(O)CH 3 .

8. The compound of claim 6 , wherein k is 0.

9. The compound of claim 6 , having the formula (III):

or a pharmaceutically acceptable salt thereof, wherein

R 11 is selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl and (C 2 -C 8 )heteroalkyl.

10. The compound of claim 3 , wherein A 4 is C(R′)(R″).

11. The compound of claim 10 , wherein A 1 , A 2 and A 3 are C(R′)(R″).

12. The compound of claim 11 , having the formula (IV):

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 11 , having the formula (V):

or a pharmaceutically acceptable salt thereof, wherein

each R a is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )heteroalkyl, fluoro(C 1 -C 4 )alkyl, aryl, heteroaryl, aryl(C 1 -C 8 )alkyl and heteroaryl(C 1 -C 8 )alkyl, optionally, R a groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and R a groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring; and

the subscript p is 0, 1, 2, 3 or 4.

14. The compound of claim 13 , having the formula (VI):

or a pharmaceutically acceptable salt thereof, wherein

R 11 is selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl and (C 2 -C 8 )heteroalkyl.

15. The compound of claim 14 , wherein R 3 is a member selected from the group consisting of —H, —SO 2 CH 3 , —SO 2 CH 2 CH 3 ,

16. The compound according to claim 4 or 10 , wherein -L-R 3 when taken together is

17. The compound of claim 4 or 10 , wherein R 1 is a unsubstituted or a meta- or para-substituted phenyl, wherein the substituting group is a halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, oxy(C 1 -C 8 )alkyl, or oxy(C 1 -C 8 )haloalkyl.

18. The compound of claim 4 or 10 , wherein R 1 is a meta- or para-substituted phenyl, wherein the substituting group is a cyano.

19. The compound of claim 4 or 10 , wherein R 2 is a member selected from the group consisting of

20. The compound of claim 4 or 10 , wherein Q is —C(O)—.

21. The compound of claim 4 or 10 , wherein L is a bond, —CH 2 — or —CH 2 CH 2 —.

22. The compound of claim 4 or 10 , wherein -Q-R 4 is

23. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

24. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt.